AstraZeneca is investing $2 billion to expand its long-standing manufacturing footprint in Maryland. This includes an expansion of its flagship biologics manufacturing facility in Frederick and construction of a new facility in Gaithersburg for the development and clinical supply of innovative molecules to be used in clinical trials. The investment will support 2,600 jobs across the two sites in the state including the retention of local roles, construction activity, and the creation of 300 h...